Cost Per Response for Abatacept Compared with Adalimumab In the Treatment of Patients with Rheumatoid Arthritis Based on Anti-Citrullinated Protein Antibody Titres In Italy

  • Foo J
  • Mennini F
  • Rodriguez Heredia J
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Objectives: Effective treatment with biologic DMARDs poses a significant economic burden. Recent subgroup analyses showed improved efficacy for abatacept in serum anti-citrullinated protein antibody (ACPA)-positive patients, with increasing efficacy across ACPA quartile levels. The aim of the study was to evaluate the cost per response of abatacept relative to adalimumab in ACPA-positive patients with RA from the Italian societal perspective. Methods: A decision tree was designed to compare the cost per response of abatacept with adalimumab in a cohort of 1000 ACPA-positive patients over 2 years. Clinical inputs were based on the Abatacept versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate AMPLE trial, and response was based on ACR20/50/70/90 and HAQ-DI. Unit costs for direct medical costs of AEs were based on Italian tariffs for diseaserelated groups and the ex-manufacturer's price, including mandatory reductions, payback and transparent discounts for drugs. Societal costs included patient costs, indirect costs of work absence and early retirement, according to HAQ functional capacity categories. Results: Cost per response in ACPA-positive patients in Italy favoured abatacept compared with adalimumab (- € 154 for ACR20, - € 6,426 considering ACR90 and - € 281 for HAQ-DI). Cost per remission favoured abatacept in ACPA-positive patients with a cost reduction per CDAI and SDAI equal to € 744 and € 1,310 respectively. Abatacept was consistently favoured in ACPA-Q4 patients across all outcomes in Italy. Conclusions: The cost per selected outcome in ACPA-positive patients favoured SC abatacept compared with SC adalimumab. The costs per all outcomes were lower for SC abatacept than SC adalimumab in ACPA-Q4 patients in Italy. Cost savings were greater when more stringent response criteria were applied and also with increasing ACPA levels, which could lead to a lower overall healthcare budget impact with abatacept compared with adalimumab in Italy.

Cite

CITATION STYLE

APA

Foo, J., Mennini, F., Rodriguez Heredia, J., Choquette, D., Attinà, G., Merino, J., … Gaultney, J. (2017). Cost Per Response for Abatacept Compared with Adalimumab In the Treatment of Patients with Rheumatoid Arthritis Based on Anti-Citrullinated Protein Antibody Titres In Italy. Value in Health, 20(9), A531. https://doi.org/10.1016/j.jval.2017.08.751

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free